- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00798005
Efficacy and Safety Study of NV1FGF in Patients With Severe Peripheral Artery Occlusive Disease. (TALISMAN202)
A Phase II, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Efficacy and Safety Study of Different Doses and Schedules of Administration of NV1FGF in Patients With Severe Peripheral Artery Occlusive Disease.
Peripheral Arterial Occlusive Disease (PAOD) is a condition caused by ischemia in the legs due to atherosclerotic disease affecting the larger arteries of the legs. Chronic PAOD can be regarded as a marker of generalized atherosclerosis. PAOD threatens the survival of an extremity and often causes lifelong disablement from a painful leg. The clinical consequences of PAOD include pain on walking (claudication), pain at rest and loss of tissue integrity in the distal limbs.A variety of medical therapies have been investigated for patients with PAOD. There is currently no evidence to suggest that any medical therapy is effective for patients with rest pain and/or ischemic ulcers.
Also, the use of intramuscular angiogenic VEGF-A gene transfer has recently demonstrated a improvement in clinical and hemodynamic status in patients with severe PAOD
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
New Jersey
-
Bridgewater, New Jersey, United States
- Sanofi-Aventis Administrative Office
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Informed consent was to be signed before proceeding with any study procedure.
- Patients with severe PAD.
- Trophic lesions with no signs of healing (no reduction in ulcer size or depth) for at least 2 weeks prior to first study treatment administration (Day 1).
- Patients with objective evidence of peripheral vascular disease in the diseased limb on 2 consecutive examinations performed at least 1 week apart.
- Demonstration or documentation of total occlusion of the affected limb of one or more of the iliac, superficial femoral, popliteal and/or one or more infrapopliteal arteries as assessed by angiography or magnetic resonance angiography (MRA)
- Transcutaneous oxygen pressure (TcPO2): mean resting supine TcPO2 of the foot of ≤40 mmHg based on 2 separate measures performed at least 1 week apart
- Poor/not candidates for revascularization
Exclusion criteria
- Previous or current history of malignant disease.
- Positive cancer screening (liver, prostate, colon, cervix, breast, lung)
- Successful lower extremity surgery (bypass/angioplasty of the leg to be treated) within 3 months prior to the first administration of study treatment [Day 1]).
- Patients planned to undergo amputation of target limb within 1 month following the first administration of study treatment.
- Patients with a history of severe renal failure.
- Creatinine >2.0 mg/dL (176 µmol/L) or estimated creatinine clearance <30 mL.
- Serious concomitant medical conditions not adequately controlled (other than severe PAD),
- Buerger's disease.
- Patients in dialysis.
- Active proliferative retinopathy
- Patients who had a stroke or neurologic deficit presumed to be due to stroke within 3 months prior to the first administration of study treatment.
- Previous treatment with any angiogenic growth factor.
- Positive serology for HIV 1 or 2.
- Participation in clinical trials of non-approved experimental agents within 4 weeks before study entry.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
evaluate the efficacy and the safety of NV1FGF compared to placebo in patients with severe PAOD.
|
Secondary Outcome Measures
Outcome Measure |
---|
evaluate the biodistribution of NV1FGF and to measure serum levels of antibodies against FGF-1
|
Collaborators and Investigators
Sponsor
Publications and helpful links
General Publications
- Niebuhr A, Henry T, Goldman J, Baumgartner I, van Belle E, Gerss J, Hirsch AT, Nikol S. Long-term safety of intramuscular gene transfer of non-viral FGF1 for peripheral artery disease. Gene Ther. 2012 Mar;19(3):264-70. doi: 10.1038/gt.2011.85. Epub 2011 Jun 30.
- Henry TD, Mendelsohn F, Comerota A, Pham E, Grek V, Coleman M, Meyer F, Annex B Dose and regimen effects of intramuscular NV1FGF in patients with critical limb ischemia: A randomized, double-blind, placebo controlled study. Eur H J 2006, 27 Suppl 1 Abs P1497
Helpful Links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- DRI6144
- NV1FGF-PM202
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Severe Peripheral Artery Occlusive Disease
-
Losordo, Douglas, M.D.UnknownPeripheral Artery Disease | Severe Intermittent ClaudicationUnited States
-
Marissa JarosinskiRecruitingPeripheral Arterial Occlusive Disease | Peripheral Vascular Disease | Peripheral Artery Disease | Clopidogrel, Poor Metabolism of | Artery DiseaseUnited States
-
TCA Cellular TherapyCompletedPeripheral Vascular Disease | Peripheral Artery Disease | Critical Limb Ischemia | Severe Leg IschemiaUnited States
-
Boston Scientific CorporationCompletedAtherosclerosis | Peripheral Artery Disease | Plaque, Atherosclerotic | Artery Diseases, Peripheral | Occlusive Arterial DiseaseUnited States, Belgium, Canada, Japan, Austria, New Zealand
-
CID S.p.A.Meditrial Europe Ltd.Not yet recruitingPeripheral Arterial Occlusive Disease | Peripheral Artery DiseaseItaly
-
Helsinki University Central HospitalCompletedPeripheral Artery Occlusive Disease | Peripheral Artery Stenosis | Peripheral Artery RestenosisFinland
-
University of NebraskaNot yet recruitingPeripheral Arterial Disease | Peripheral Vascular Diseases | Peripheral Arterial Occlusive Disease | Peripheral Artery DiseaseUnited States
-
Fangge DengRecruitingPeripheral Artery Disease (PAD)China
-
Fundacion para la Formacion e Investigacion Sanitarias...Not yet recruiting
-
Rontis Hellas SAPharmassist LtdActive, not recruitingPeripheral Artery Disease (PAD)Greece
Clinical Trials on XRP0038 (NV1FGF)
-
SanofiCompletedPeripheral Arterial DiseaseUnited Kingdom, Belgium, France, Germany, Italy, Switzerland
-
SanofiCompletedPeripheral Arterial Occlusive DiseaseUnited States, Belgium, Germany, Switzerland
-
SanofiCompletedEfficacy and Safety of XRP0038/NV1FGF in Critical Limb Ischemia Patients With Skin Lesions (TAMARIS)Peripheral Vascular DiseasesFrance, Canada, Brazil, Poland, Russian Federation, Ukraine, Germany, Spain, Sweden, Switzerland, United States, Turkey, Singapore, Belgium, Czech Republic, Mexico, Japan, Austria, Denmark, Finland, Hungary, Italy, Korea, Republic of, Chil... and more
-
SanofiCompletedPeripheral Arterial Occlusive DiseaseUnited States, Finland
-
SanofiCompletedPeripheral Arterial Occlusive DiseaseUnited States, Switzerland